An interventional study of Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lenses in Children With Myopia, Treatment and Multizone Lens Design for Myopic Defocus, sponsored by Beijing Tongren Hospital. Recruiting at 1 site in China. Open to participants aged 6 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Beijing Tongren Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Myopia by Beijing Tongren Hospital — 10 open to participants now, 11 under way, none of them phase 3. Myopia · Beijing Tongren Hospital.
Among the 22 studies in Myopia by Beijing Tongren Hospital, this one is the 9th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2024, is one of 14 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 13th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →10 of the 22 studies in Myopia by Beijing Tongren Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tongren Hospital · Sites in China
Healthy volunteers
Beijing Tongren Hospital · Sites in China
Ages 6–16
Beijing Tongren Hospital · Sites in China
Ages 6–9 · Healthy volunteers
Beijing Tongren Hospital · Sites in China
Ages 7–18 · Healthy volunteers
Beijing Tongren Hospital · Sites in China
Ages 6–12 · Healthy volunteers
By country, each count listing its studies:
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 6 Years to 14 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 120 across the 17 interventional studies, 2,000 across the 5 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tongren Hospital is the lead sponsor of 165 studies on the registry; 54 are open to participants now.
4 of the studies in Myopia by Beijing Tongren Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07724210Beijing Tongren HospitalEffectiveness of Digital Defocus Vision Training With Low-Concentration Atropine on the Prevention and Control of Myopia in Children: A Clinical Study | 2026-12-31 |
| NCT05786586Beijing Tongren Hospital650nm Low-level Red-light for Myopia Control and Prevention in Children | 2026-12-31 |
| NCT07412678Beijing Tongren HospitalEvaluation of the Efficacy of Red Light in Adult Patients With High and Extreme Myopia | 2027-03-11 |
| NCT07946094Beijing Tongren HospitalEvaluation of the Effect of Comprehensive Myopia Control Interventions on Myopia Prevention and Control | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies in Myopia by Beijing Tongren Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical Trial
The goal of this clinical trial is to evaluate the effectiveness of two types of Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lenses in slowing myopia progression in children. It will also assess the safety of these lenses. The main questions it aims to answer are:
Do D.S.D.O. lenses reduce the progression of myopia as measured by changes in cycloplegic refraction and axial length? What adverse events do participants experience when wearing D.S.D.O. lenses? Researchers will compare two optical designs of D.S.D.O. lenses (Intervention Group1: Design 1; Intervention Group2: Design 2) to determine their relative efficacy in controlling myopia progression.
Participants will:
Wear assigned D.S.D.O. lenses daily for 12 months (except during sleep or unavoidable situations).
Attend clinic visits at baseline, 3, 6, 9, and 12 months for comprehensive eye examinations.
Maintain a diary recording daily wear time, visual symptoms, and any adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lenses
Device: Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lenses
This clinical trial employs a randomized, parallel-group, superiority design to evaluate two novel optical designs of Diverse Segments Defocus Optimization (D.S.D.O.) myopia management spectacle lenses. A total of 60 myopic Chinese children, aged 6 to 14 years, will be recruited and randomly assigned in a 1:1 ratio to one of two intervention groups. Both groups will receive myopia control spectacles: the Control Group will use D.S.D.O. Lens Design 1, and the Intervention Group will use D.S.D.O. Lens Design 2. Participants are required to wear the assigned spectacles daily for the entire 12-month study duration, except during sleep or other unavoidable circumstances. The spectacles are intended to provide full refractive correction for distance vision while simultaneously incorporating defocus modifications designed to slow myopia progression by manipulating peripheral retinal defocus patterns. The study includes a baseline visit, a dispensing visit, and follow-up assessments at 3, 6, 9
Change in Spherical Equivalent Refraction (SER)
Time frame: From enrollment to the end of treatment at 12 months
Started Aug 2024 (actual). Primary completion is estimated for Sep 2026, 25 months after the start.
Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 25 months is close to that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.